Larimar Therapeutics, Inc.
LRMRNASDAQ
Healthcare
Biotechnology
$4.76
+0.09(1.8%)
52W $1.71 – $5.95
Larimar Therapeutics, Inc.
$408MMkt Cap
—Rev TTM
-$166MNI TTM
-2.4xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 18, 2026Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotech focused on nomlabofusp for Friedreich's ataxia, reported a FY 2025 net loss of $165.7 million, widening from $80.6 million in 2024, primarily due to surging research and development expenses of $154.2 million (up from $73.3 million) driven by nomlabofusp manufacturing scale-up, clinical studies, and process qualification. General and administrative expenses rose slightly to...
What Changed Recently
Fundamentals
How The Business Makes Money
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Industry Biotechnology
Company Profile
CIK0001374690
ISINUS5171251003
CUSIP517125100
Phone844 511 9056
AddressThree Bala Plaza East, Bala Cynwyd, PA, 19004, US
SEC EDGAR